Two analyses support use of osimertinib for patients with Stage IB to IIIA non-small cell lung cancer
New COVID-19 forecasts show the possibility of a spring spike in deaths with new variants
29 January 2021Kentucky Office of Rural Health announces elder wellness award recipients
29 January 2021Two analyses support use of osimertinib for patients with Stage IB to IIIA non-small cell lung cancer
Two presentations from the ADAURA clinical trial advanced previous research that demonstrated improved disease-fee survival (DFS) outcomes for patients with surgically resected non-small cell lung cancer (NSCLC) receiving osimertinib. The data were reported today at the International Association for the Study of Lung Cancer’s 2020 World Conference on Lung Cancer (WCLC) Singapore.
